Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Given Consensus Rating of "Moderate Buy" by Analysts

Key Points

• Agios Pharmaceuticals has been rated as a "Moderate Buy" by eight brokerages, with a consensus 12-month price target of approximately $56.33.
• Recently, CEO Brian Goff sold 18,700 shares at an average price of $33.54, representing a 15.07% decrease in his position, while total insider sales in the last ninety days reached $2,026,141.
• The company reported a quarterly loss of ($1.93) EPS, falling short of the consensus estimate, but achieved revenues of $12.50 million, exceeding analyst expectations.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) has earned an average rating of "Moderate Buy" from the eight research firms that are presently covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 12 month target price among brokers that have covered the stock in the last year is $56.3333.

Several brokerages recently issued reports on AGIO. Bank of America dropped their price objective on Agios Pharmaceuticals from $52.00 to $51.00 and set a "buy" rating on the stock in a research note on Tuesday, July 22nd. Wall Street Zen downgraded Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Monday, May 19th. Finally, Scotiabank dropped their price target on Agios Pharmaceuticals from $71.00 to $65.00 and set a "sector outperform" rating on the stock in a research report on Monday, July 28th.

Agios Pharmaceuticals Stock Up 3.5%

AGIO traded up $1.33 on Monday, reaching $39.53. 136,710 shares of the company traded hands, compared to its average volume of 703,037. Agios Pharmaceuticals has a one year low of $23.42 and a one year high of $62.58. The firm has a fifty day simple moving average of $36.73 and a two-hundred day simple moving average of $32.86. The company has a market cap of $2.30 billion, a P/E ratio of 3.60 and a beta of 0.80.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported ($1.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.74) by ($0.19). Agios Pharmaceuticals had a negative return on equity of 3.49% and a net margin of 1,590.42%.The firm had revenue of $12.50 million during the quarter, compared to the consensus estimate of $9.46 million. On average, equities analysts forecast that Agios Pharmaceuticals will post -6.85 earnings per share for the current year.

Insider Buying and Selling at Agios Pharmaceuticals

In other news, CEO Brian Goff sold 18,700 shares of the stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $33.54, for a total transaction of $627,198.00. Following the transaction, the chief executive officer owned 105,401 shares of the company's stock, valued at approximately $3,535,149.54. This represents a 15.07% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Cecilia Jones sold 1,780 shares of the stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $33.54, for a total value of $59,701.20. Following the sale, the chief financial officer directly owned 30,049 shares in the company, valued at $1,007,843.46. This trade represents a 5.59% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 57,448 shares of company stock worth $2,026,141. Insiders own 4.30% of the company's stock.

Institutional Trading of Agios Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of AGIO. GF Fund Management CO. LTD. bought a new stake in Agios Pharmaceuticals during the 4th quarter valued at $39,000. NewEdge Advisors LLC bought a new stake in Agios Pharmaceuticals during the 1st quarter valued at $40,000. CWM LLC boosted its position in Agios Pharmaceuticals by 150.2% during the 1st quarter. CWM LLC now owns 1,659 shares of the biopharmaceutical company's stock valued at $49,000 after acquiring an additional 996 shares in the last quarter. Sterling Capital Management LLC boosted its position in Agios Pharmaceuticals by 818.0% during the 4th quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company's stock valued at $59,000 after acquiring an additional 1,587 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in Agios Pharmaceuticals by 16.7% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,237 shares of the biopharmaceutical company's stock valued at $74,000 after acquiring an additional 320 shares in the last quarter.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.